<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS RESTATED SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED FINANCIAL STATEMENTS OF GENZYME CORPORATION AND SUBSIDIARIES AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS AS PRESENTED
IN THE 1996 ANNUAL REPORT ON FORM-10K FOR GENZYME CORPORATION.
</LEGEND>
<RESTATED>
<CURRENCY> U.S. DOLLARS
       
                             
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<EXCHANGE-RATE>                                      1
<CASH>                                          93,132
<SECURITIES>                                    56,608
<RECEIVABLES>                                  116,833
<ALLOWANCES>                                    16,508
<INVENTORY>                                    125,265
<CURRENT-ASSETS>                               509,618
<PP&E>                                         393,839
<DEPRECIATION>                                  20,172
<TOTAL-ASSETS>                               1,270,508
<CURRENT-LIABILITIES>                          114,013
<BONDS>                                        241,998
<PREFERRED-MANDATORY>                              887
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                     901,422
<TOTAL-LIABILITY-AND-EQUITY>                 1,270,508
<SALES>                                        424,483
<TOTAL-REVENUES>                               518,754
<CGS>                                          155,930
<TOTAL-COSTS>                                  210,012
<OTHER-EXPENSES>                               384,066
<LOSS-PROVISION>                                 8,338
<INTEREST-EXPENSE>                               6,990
<INCOME-PRETAX>                               (69,622)
<INCOME-TAX>                                   (3,195)
<INCOME-CONTINUING>                           (72,817)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (72,817)
<EPS-PRIMARY>                                   (0.45)<F1><F2>
<EPS-DILUTED>                                   (0.45)<F1><F2>
<FN>
<F1>THE COMPANY HAS TWO CLASSES OF TRACKING STOCK WHICH ARE INTENDED TO REFLECT
THE VALUE AND TRACK THE PERFORMANCE OF GENZYME'S GENERAL DIVISION AND TISSUE
REPAIR DIVISION. EARNINGS (LOSS) PER SHARE IS REPORTED AS ATTRIBUTABLE TO EITHER
GENZYME GENERAL DIVISION COMMON STOCK ("GGD STOCK") OR GENZYME TISSUE REPAIR
DIVISION COMMON STOCK ("GTR STOCK"). CONSOLIDATED EPS IS NOT APPLICABLE FOR THE
YEAR ENDED DECEMBER 31, 1996. THE GENERAL DIVISION REPORTED A NET LOSS OF $0.45
PER SHARE OF GGD STOCK AND GTR REPORTED A NET LOSS OF $3.38 PER SHARE OF GTR
STOCK.
<F2>NET LOSS PER SHARE OF GGD STOCK AND GTR STOCK, FOR THE YEAR ENDED DECEMBER
31, 1996 COMPUTED TO CONFORM TO SFAS 128 IS THE SAME ON NET LOSS PER SHARE OF
GGD STOCK AND GTR STOCK AS COMPUTED UNDER APB 15 AS THE INCLUSION OF CERTAIN
POTENTIALLY DILUTIVE SHARES IN THE DILUTIVE LOSS PER SHARE CALCULATION FOR STOCK
WOULD HAVE BEEN ANTIDILUTIVE.
</FN>